Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,097 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor necrosis factor-alpha plays an important role in restenosis development.
Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, 't Hart LM, Frants RR, Quax PH, van Vlijmen BJ, Havekes LM, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: jukema jw. FASEB J. 2005 Dec;19(14):1998-2004. doi: 10.1096/fj.05-4634com. FASEB J. 2005. PMID: 16319143
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, Ackerstaff RA, Bruschke AV. de Groot E, et al. Among authors: jukema jw. Am J Cardiol. 1995 Sep 28;76(9):40C-46C. doi: 10.1016/s0002-9149(99)80469-x. Am J Cardiol. 1995. PMID: 7572685 Clinical Trial.
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al. Jukema JW, et al. Circulation. 1995 May 15;91(10):2528-40. doi: 10.1161/01.cir.91.10.2528. Circulation. 1995. PMID: 7743614 Clinical Trial.
Progression and regression of coronary atherosclerosis.
Bruschke AV, Jukema JW, Van der Wall EE. Bruschke AV, et al. Among authors: jukema jw. Indian Heart J. 1993 Jul-Aug;45(4):259-64. Indian Heart J. 1993. PMID: 8138275 Review. No abstract available.
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Jukema JW, Zwinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI, Bruschke AV. Jukema JW, et al. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):425-30. doi: 10.1161/01.atv.16.3.425. Arterioscler Thromb Vasc Biol. 1996. PMID: 8630669 Clinical Trial.
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
1,097 results